Chang-Ki Min

Chang-Ki Min

Auto-generated profile, based on publicly available information

Chang-Ki Min

Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2007 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
CMC-K Min
C-K Min
BKB-G Kim
B-G Kim
GPG Park
G Park
BCBin Cho
Bin Cho
IOI-H Oh
I-H Oh

2 October 2008 in Leukemia
Verified
Journal Article
Open access
PDF file
BCB-S Cho
B-S Cho
CMC-K Min
C-K Min
KEK-S Eom
K-S Eom
YKY-J Kim
Y-J Kim
HKH-J Kim
H-J Kim
CKC-C Kim
C-C Kim
To assess the applicability of the National Institutes of Health (NIH) consensus criteria (NCC) for chronic graft-versus-host disease (cGVHD), 211 patients who developed GVHD more than 100 days after allogeneic transplantation were reclassified using NCC. Classifications were: late acute GVHD (44 patients, 21%), overlap syndrome (64 patients, 30%) and classic cGVHD (103 patients, 49%). Classic cGVHD and overlap syndrome patients (n=167) were graded using both the revised Seattle criteria (RSC) and NIH global scoring (NGS). Twenty-three patients (14%) had mild, 81 (48%) had moderate and 63 (38%) had severe cGVHD. After a median follow-up of 46 months (range 5–71 months), the 4-year GVHD-specific survival was not significantly different among the different subtypes of NCC. Among patients with late acute GVHD, however, the pattern of acute GVHD onset (late, persistent or recurrent) was significantly different with respect to GVHD-specific survival. Among patients with overlap syndrome and classic cGVHD, multivariate analysis showed that NGS as well as RSC were useful in predicting survival and discontinuation of immunosuppressive therapy despite of more detailed grouping. Our study indicates that NCC is applicable. The clinical impact of NIH types and NGS should be verified through prospective studies.

1 October 2019 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
SLSung-Eun Lee
Sung-Eun Lee
JLJi-Young Lim
Ji-Young Lim
DRDa-Bin Ryu
Da-Bin Ryu
TKTae Woo Kim
Tae Woo Kim
SPSung Soo Park
Sung Soo Park
CMChang-Ki Min
Chang-Ki Min
Patients undergoing hematopoietic stem cell transplantation (HSCT) frequently receive empiric antibiotics during the neutropenic period before engraftment. Several recent studies have shown that anaerobes in the intestine are important mediators of intestinal homeostasis, and that commensal bacteria can be potent modulators of the severity of acute graft-versus-host disease (aGVHD). However, the relationships among the type of antibiotic used during the neutropenic period, changes in the intestinal microbiota, and subsequent occurrence of aGVHD are not clear. In this study, a total of 211 patients undergoing HSCT were stratified into 3 groups: patients not treated with any antibiotics during the neutropenic period (group 1; n = 43), patients treated with cefepime only (group 2; n = 87), and patients treated with carbapenem antibiotics, defined as meropenem or prepenem with or without previous cefepime therapy (group 3; n = 81). Intestinal microbiota analyses were performed on pre- and post-HSCT stool samples, and immunophenotypic analyses were performed on pre- and post-HSCT peripheral blood samples. Among the 211 patients, 95 (45%) developed aGVHD (grade ≥II), including 54 with intestinal GVHD. The incidence of intestinal GVHD was higher in group 3 compared with group 1 and group 2 (32.1%, 11.6%, and 26.4%, respectively; P = .044). After adjusting for potentially significant variables identified by univariate analysis, multivariate analyses identified broad-spectrum antibiotic use during the neutropenic period as associated with the occurrence of intestinal GVHD (hazard ratio, 3.25; 95% confidence interval, 1.13 to 9.34; P = .029). Accordingly, loss of bacterial diversity in terms of alterations in intestinal microbiota after HSCT was observed in patients who received broad-spectrum antibiotics. Moreover, alterations in the frequencies of several intestinal bacteria phyla were associated with the occurrence of intestinal GVHD. Evaluation of circulating immune cell subsets according to type of antibiotic used during the neutropenic period revealed delayed recovery of myeloid-derived suppressor cells in the broad-spectrum antibiotic use group. Our data indicate that the use of broad-spectrum antibiotics during the neutropenic period is associated with a higher incidence of intestinal GVHD via loss of microbiome diversity. Further studies are needed to determine whether maintaining bacterial diversity can help prevent the development of aGVHD.

21 January 2008 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
BCB-S Cho
B-S Cho
CMC-K Min
C-K Min
KEK-S Eom
K-S Eom
YKY-J Kim
Y-J Kim
HKH-J Kim
H-J Kim
CKC-C Kim
C-C Kim
The impact of thrombotic microangiopathy (TMA) on outcome was studied in 148 patients with acute graft-versus-host disease (GVHD) (grade II). The Blood and Marrow Transplant Clinical Trials Network's definition for TMA was used to diagnose definite TMA. Probable TMA was diagnosed when none of the features of nephropathy and neurologic abnormalities associated with definite TMA were present. Overall, TMA developed in 43 (29%) patients; 16 definite and 27 probable. The occurrence of TMA, the maximum grade of acute GVHD and initial treatment failure were associated with shorter overall and GVHD-specific survival. The development of probable as well as definite TMA affected the survival of patients with acute GVHD adversely. These results show the clinical impact of TMA on patients with acute GVHD, and suggest that the proposed definitions and grading of TMA may need to be modified.

5 June 2006 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
CMC-K Min
C-K Min
SKS Y Kim
S Y Kim
MLM J Lee
M J Lee
KEK S Eom
K S Eom
YKY J Kim
Y J Kim
CCC S Cho
C S Cho

1 January 2011 in The Korean Journal of Hematology
Verified
Journal Article
Open access
PDF file
CMChang-Ki Min
Chang-Ki Min
Min CK. Korean J Hematol. 2011 Jun;46(2):80-87. http://dx.doi.org/10.5045/kjh.2011.46.2.80